Phase 3CompletedAge-related condition

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)

A Multicenter, Randomized, Double-blind, Double Dummy, Active-controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate the Efficacy and Safety of CWP-0403 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DM Insufficiently Controlled With Metformin Alone

Sponsor
JW Pharmaceutical (Industry)
Enrollment
200 planned
Conditions
Type 2 Diabetes Mellitus
Interventions
Anagliptin; Sitagliptin
Ages
adults, older adults
Registry
NCT01529541

Full record on ClinicalTrials.gov

From the registry

This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.

Primary outcomes

  • The Change in HbA1c from baseline to week24.

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started